General Information of Drug Combination (ID: DCOILLV)

Drug Combination Name
Acamprosate Clascoterone
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Acamprosate   DMO381I Clascoterone   DMPGR1E
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 5.23
Bliss Independence Score: 5.23
Loewe Additivity Score: 23.67
LHighest Single Agent (HSA) Score: 23.67

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Acamprosate
Disease Entry ICD 11 Status REF
Alcohol dependence 6C40.2 Approved [2]
Acamprosate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glutamate receptor AMPA (GRIA) TTAN6JD NOUNIPROTAC Agonist [4]
------------------------------------------------------------------------------------
Indication(s) of Clascoterone
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [3]
Clascoterone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Androgen receptor (AR) TTS64P2 ANDR_HUMAN Antagonist [3]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7106).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37.